

F. No. 4-01/2017- DC (Misc.78)
Central Drugs Standard Control Organization
Directorate of General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, New Delhi

13th July, 2017.

NOTICE


Subject: Availability of essential medicines following implementation of GST- regarding

It has been reported in press that essential medicines for treatment of Diabetes and other diseases are in short supply following implementation of GST across India. In the report, it has been alleged that due to financial loss because of implementation of GST, the drug companies are not releasing their products into the market although stock of hundreds of crores are kept in godowns.

On the representation of Industry Associations like FICCI, IDMA, IPA and others regarding allowing alteration of labels (stickering) due to implementation of GST, this Office has taken proactive measures and issued a Notice dated 10.07.2017 that this office has no objection for alteration of label (stickering) by the manufacturers under rule 104A of the Drugs and Cosmetics Rules, 1945, if required, for effective implementation of GST subject to provisions of Legal Metrology Act & Rules and other provisions of Act and Rules relating to Goods & Service Tax. This Notice has already been posted on the CDSCO website (copy enclosed).

The said Notice has been issued to facilitate the manufacturers for switching over to the new regime of GST smoothly so that medicines could be made available to the patients without any regulatory hurdles.

You are, therefore, requested to take appropriate measures to ensure availability of essential medicines in your respective territories. Assistance, if any, required from CDSCO would be welcomed.


(Dr. G.N. Singh)
Drugs Controller General (India)

Encls: As above

To

All State/UT Drug Controllers

Copy for information and necessary action to:

1. Pharma Associations - FICCI/IDMA/IPA/OPPI/FOPE/CIPI/All India Chemists & Druggists Association
2. Heads, Zonal and Sub-Zonal offices of CDSCO
3. Joint Secretary, Department of Pharmaceuticals
4. PPS to DGHS
5. PS to JS(R), MOHFW
6. Website of CDSCO